Longeveron is a life-sciences company developing biological solutions for aging and aging-associated diseases. They believe regenerative medicine, through cell-based therapy, is a promising new approach to treating these conditions. Participating in FDA-evaluated clinical trials, Longeveron is currently testing their cell-based therapy product for a diagnosable ailment called Aging Frailty, a growing condition impacting approximately 50 million Americans over the age of 60.
